Scholarlink

Purpose <p>This study aimed to assess the clinical and cost-effectiveness of telerehabilitation (TELE) compared to face-to-face rehabilitation (FTF) in patients following arthroscopic ACL reconstruction. Given the increasing demand for accessible rehabilitation methods, this trial investigates the feasibility of implementing TELE in a middle-income country like China.</p> Methods <p>A prospective, non-inferiority randomized controlled trial (RCT) was conducted with 68 participants randomly assigned to either TELE or FTF rehabilitation. Participants were followed for 12&#xa0;weeks, with assessments at baseline, 6&#xa0;weeks, and 12&#xa0;weeks after surgery. Primary outcomes included knee function (measured using the International Knee Documentation Committee Subjective Knee Form, IKDC). Secondary outcomes included pain, mobility, and functional status. Cost-effectiveness was analyzed using the incremental cost-effectiveness ratio (ICER).</p> Results <p>Both groups showed similar improvements in clinical outcomes, with no significant differences in IKDC scores, pain levels, or range of motion at 12&#xa0;weeks. However, TELE rehabilitation was significantly less expensive, with a total cost of 58,303.18 CNY compared to 82,358.90 CNY for FTF (<i>p</i> &lt; 0.001). The ICER analysis demonstrated that TELE was a cost-effective alternative, with substantial cost savings per unit of effectiveness.</p> Conclusion <p>Telerehabilitation may be a cost-effective and clinically comparable alternative to traditional face-to-face rehabilitation following ACL reconstruction. These findings may support the broader implementation of TELE in regions with limited access to in-person rehabilitation, especially in low- and middle-income countries like China. Further studies with longer follow-up periods are needed to confirm the long-term cost-effectiveness and health benefits of TELE.</p> Trial registration <p>Chinese Clinical Trial Registry (<a href="https://www.chictr.org.cn/">https://www.chictr.org.cn/</a>). Trial registration ChiCTR2100053313.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The efficacy and cost-effectiveness analysis of telerehabilitation for patients after arthroscopic ACL-reconstruction: a non-inferiority randomized controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月24日

查看全文
  • Chenrui Yuan,
  • Caiqi Xu,
  • Lihua Huang,
  • Yaohua He,
  • Shengdi Lu

摘要

Purpose

This study aimed to assess the clinical and cost-effectiveness of telerehabilitation (TELE) compared to face-to-face rehabilitation (FTF) in patients following arthroscopic ACL reconstruction. Given the increasing demand for accessible rehabilitation methods, this trial investigates the feasibility of implementing TELE in a middle-income country like China.

Methods

A prospective, non-inferiority randomized controlled trial (RCT) was conducted with 68 participants randomly assigned to either TELE or FTF rehabilitation. Participants were followed for 12 weeks, with assessments at baseline, 6 weeks, and 12 weeks after surgery. Primary outcomes included knee function (measured using the International Knee Documentation Committee Subjective Knee Form, IKDC). Secondary outcomes included pain, mobility, and functional status. Cost-effectiveness was analyzed using the incremental cost-effectiveness ratio (ICER).

Results

Both groups showed similar improvements in clinical outcomes, with no significant differences in IKDC scores, pain levels, or range of motion at 12 weeks. However, TELE rehabilitation was significantly less expensive, with a total cost of 58,303.18 CNY compared to 82,358.90 CNY for FTF (p < 0.001). The ICER analysis demonstrated that TELE was a cost-effective alternative, with substantial cost savings per unit of effectiveness.

Conclusion

Telerehabilitation may be a cost-effective and clinically comparable alternative to traditional face-to-face rehabilitation following ACL reconstruction. These findings may support the broader implementation of TELE in regions with limited access to in-person rehabilitation, especially in low- and middle-income countries like China. Further studies with longer follow-up periods are needed to confirm the long-term cost-effectiveness and health benefits of TELE.

Trial registration

Chinese Clinical Trial Registry (https://www.chictr.org.cn/). Trial registration ChiCTR2100053313.